The pharmaceutical continuous manufacturing market size has grown rapidly in recent years. It will grow from $2.26 billion in 2023 to $2.5 billion in 2024 at a compound annual growth rate (CAGR) of 10.5%.The growth observed in the historic period can be credited to several key factors. Quality and efficiency improvements played a significant role, enhancing the overall performance of processes. The reduction in time-to-market for pharmaceutical products contributed to quicker availability and responsiveness to market needs. Cost reduction and operational efficiency measures were implemented, optimizing resource utilization and enhancing the financial viability of pharmaceutical operations. Regulatory support and adherence to guidelines ensured compliance and streamlined approval processes. The incorporation of flexibility and scalability in operations allowed for adaptability to changing market dynamics and varying production demands, contributing to sustained growth in the pharmaceutical industry.
The pharmaceutical continuous manufacturing market size is expected to see rapid growth in the next few years. It will grow to $3.71 billion in 2028 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to increasing generic drug production, biopharmaceutical manufacturing, personalized medicine manufacturing, focus on patient-centric approaches. Major trends in the forecast period include adoption of continuous manufacturing, integration of process analytical technology, use of advanced automation and robotics, strategic collaborations and partnerships, digitalization and connectivity.
The anticipated growth in the pharmaceutical continuous manufacturing market is expected to be driven by several key factors. Firstly, the increasing prevalence of chronic ailments is poised to be a significant driver. Chronic diseases, persisting for a year or longer and requiring ongoing medical treatment, are becoming more prevalent globally. Pharmaceutical continuous manufacturing processes offer a streamlined approach to drug production, enhancing efficiency and reducing costs. This approach is particularly advantageous for managing chronic conditions that necessitate long-term medication use. For example, a report by the National Association of Chronic Disease Directors highlighted that nearly 60% of adult Americans have at least one chronic disease, with around 40% having multiple chronic conditions. The economic impact of these conditions is expected to reach $2 trillion annually in the United States by 2030. Thus, the demand for pharmaceutical continuous manufacturing is likely to rise in response to the growing prevalence of chronic ailments.
The surge in industrial automation is expected to contribute significantly to the growth of the pharmaceutical continuous manufacturing market. Industrial automation involves the use of control systems, such as computers or robots, to manage various processes and machinery in industries, reducing or replacing human intervention. In the context of pharmaceutical continuous manufacturing, industrial automation facilitates real-time monitoring and feedback control, minimizing human error and ensuring consistent product quality. The notable increase in the installation of new industrial robots worldwide, as reported by the International Federation of Robotics, indicates a growing trend towards automation. With a year-on-year growth rate of 31% in 2021 and a total of approximately 3.5 million operational robots globally, industrial automation is proving to be a driving force behind the growth of the pharmaceutical continuous manufacturing market.
Technological innovations are emerging as a prominent trend in the pharmaceutical continuous manufacturing market, with major companies actively developing new products to maintain their market positions. One notable example is the introduction of the USP Advanced Manufacturing Technology Lab by The United States Pharmacopeia (USP) in December 2022. This initiative includes the launch of R&D analytical solutions aimed at assisting drug manufacturers in adopting advanced manufacturing technologies, such as pharmaceutical continuous manufacturing (PCM). The goal is to enhance geographic diversity in pharmaceutical manufacturing, thereby bolstering the resilience of the medicine supply chain. The lab services provided by USP facilitate the characterization of materials and the development and qualification of methods to ensure the quality of PCM-based medications.
Major companies in the pharmaceutical continuous manufacturing market are focusing on the development of advanced equipment, such as continuous manufacturing lines, to gain a competitive edge. For instance, WuXi STA, a China-based contract research development, and manufacturing organization (CRDMO), launched a Continuous Manufacturing (CM) line for oral solids in January 2023. This CM line, compliant with global cGMP regulations, introduces advancements in oral drug development by incorporating continuous direct compression equipment for various processes, including dispensing, blending, lubrication, tablet compression, and coating. Process Analytical Technology (PAT) is integrated into the system to monitor blending uniformity in real-time, ensuring high product quality.
In January 2023, Cambrex Corporation, a US-based contract development manufacturing organization (CDMO) for pharmaceuticals, acquired Snapdragon Chemistry Inc. This acquisition strengthened Cambrex's expertise in active pharmaceutical ingredient (API) process development in continuous flow manufacturing. Snapdragon Chemistry Inc., a US-based company specializing in API batch and continuous flow process development, was integrated to complement Cambrex's recent investments in endless flow process development capabilities. These initiatives collectively showcase the industry's commitment to leveraging technological innovations for advancements in pharmaceutical continuous manufacturing.
Major companies operating in the pharmaceutical continuous manufacturing market report are Pfizer Inc., Robert Bosch GmbH, Siemens AG, Novartis AG, Thermo Fisher Scientific Inc., GlaxoSmithKline Plc., Eli Lilly and Company, Corning Inc., Vertex Pharmaceuticals, Lonza Group Ltd., GEA Group AG, Catalent Inc., Mettler Toledo, Patheon, Cytiva, Samsung Biologics Co.Ltd., WuXi Biologics, Syntegon Technology GmbH, Coperion GmbH, Hosokawa Micron Group, FUJIFILM Diosynth Biotechnologies, Leistritz AG, Glatt GmbH, Freund-Vector Corp., SK biotek Co. Ltd., Gericke AG, GEBRÜDER LÖDIGE MASCHINENBAU GmbH, Munson Machinery Company Inc., L.B. Bohle Maschinen und Verfahren GmbH, KORSCH AG, Chemtrix BV.
Western Europe was the largest region in the pharmaceutical continuous manufacturing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical continuous manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmaceutical continuous manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary categories of pharmaceutical continuous manufacturing products include integrated continuous systems, controls and software, and semi-continuous systems. The Integrated Continuous System (ICS) represents a comprehensive method for producing pharmaceutical items seamlessly on a continuous production line. These systems find application in the manufacturing of both large molecule and small molecule therapeutics, playing a vital role in producing solid formulations, liquids, and semi-solid formulations. ICS is deployed in various applications, including final drug product manufacturing and active pharmaceutical ingredient (API) manufacturing. This technology is adopted by diverse end-users such as pharmaceutical companies, contract manufacturing organizations, and other relevant entities in the pharmaceutical industry.
The pharmaceutical continuous manufacturing market research report is one of a series of new reports that provides pharmaceutical continuous manufacturing market statistics, including pharmaceutical continuous manufacturing industry global market size, regional shares, competitors with a pharmaceutical continuous manufacturing market share, detailed pharmaceutical continuous manufacturing market segments, market trends, and opportunities, and any further data you may need to thrive in the pharmaceutical continuous manufacturing industry. This pharmaceutical continuous manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The pharmaceutical continuous manufacturing market consists of revenues earned by entities by providing manufacturing services such as mixing, granulation, coating, and tablet compression. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharmaceutical continuous manufacturing market also includes sales of organic PCM and inorganic PCM techniques. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The pharmaceutical continuous manufacturing market size is expected to see rapid growth in the next few years. It will grow to $3.71 billion in 2028 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to increasing generic drug production, biopharmaceutical manufacturing, personalized medicine manufacturing, focus on patient-centric approaches. Major trends in the forecast period include adoption of continuous manufacturing, integration of process analytical technology, use of advanced automation and robotics, strategic collaborations and partnerships, digitalization and connectivity.
The anticipated growth in the pharmaceutical continuous manufacturing market is expected to be driven by several key factors. Firstly, the increasing prevalence of chronic ailments is poised to be a significant driver. Chronic diseases, persisting for a year or longer and requiring ongoing medical treatment, are becoming more prevalent globally. Pharmaceutical continuous manufacturing processes offer a streamlined approach to drug production, enhancing efficiency and reducing costs. This approach is particularly advantageous for managing chronic conditions that necessitate long-term medication use. For example, a report by the National Association of Chronic Disease Directors highlighted that nearly 60% of adult Americans have at least one chronic disease, with around 40% having multiple chronic conditions. The economic impact of these conditions is expected to reach $2 trillion annually in the United States by 2030. Thus, the demand for pharmaceutical continuous manufacturing is likely to rise in response to the growing prevalence of chronic ailments.
The surge in industrial automation is expected to contribute significantly to the growth of the pharmaceutical continuous manufacturing market. Industrial automation involves the use of control systems, such as computers or robots, to manage various processes and machinery in industries, reducing or replacing human intervention. In the context of pharmaceutical continuous manufacturing, industrial automation facilitates real-time monitoring and feedback control, minimizing human error and ensuring consistent product quality. The notable increase in the installation of new industrial robots worldwide, as reported by the International Federation of Robotics, indicates a growing trend towards automation. With a year-on-year growth rate of 31% in 2021 and a total of approximately 3.5 million operational robots globally, industrial automation is proving to be a driving force behind the growth of the pharmaceutical continuous manufacturing market.
Technological innovations are emerging as a prominent trend in the pharmaceutical continuous manufacturing market, with major companies actively developing new products to maintain their market positions. One notable example is the introduction of the USP Advanced Manufacturing Technology Lab by The United States Pharmacopeia (USP) in December 2022. This initiative includes the launch of R&D analytical solutions aimed at assisting drug manufacturers in adopting advanced manufacturing technologies, such as pharmaceutical continuous manufacturing (PCM). The goal is to enhance geographic diversity in pharmaceutical manufacturing, thereby bolstering the resilience of the medicine supply chain. The lab services provided by USP facilitate the characterization of materials and the development and qualification of methods to ensure the quality of PCM-based medications.
Major companies in the pharmaceutical continuous manufacturing market are focusing on the development of advanced equipment, such as continuous manufacturing lines, to gain a competitive edge. For instance, WuXi STA, a China-based contract research development, and manufacturing organization (CRDMO), launched a Continuous Manufacturing (CM) line for oral solids in January 2023. This CM line, compliant with global cGMP regulations, introduces advancements in oral drug development by incorporating continuous direct compression equipment for various processes, including dispensing, blending, lubrication, tablet compression, and coating. Process Analytical Technology (PAT) is integrated into the system to monitor blending uniformity in real-time, ensuring high product quality.
In January 2023, Cambrex Corporation, a US-based contract development manufacturing organization (CDMO) for pharmaceuticals, acquired Snapdragon Chemistry Inc. This acquisition strengthened Cambrex's expertise in active pharmaceutical ingredient (API) process development in continuous flow manufacturing. Snapdragon Chemistry Inc., a US-based company specializing in API batch and continuous flow process development, was integrated to complement Cambrex's recent investments in endless flow process development capabilities. These initiatives collectively showcase the industry's commitment to leveraging technological innovations for advancements in pharmaceutical continuous manufacturing.
Major companies operating in the pharmaceutical continuous manufacturing market report are Pfizer Inc., Robert Bosch GmbH, Siemens AG, Novartis AG, Thermo Fisher Scientific Inc., GlaxoSmithKline Plc., Eli Lilly and Company, Corning Inc., Vertex Pharmaceuticals, Lonza Group Ltd., GEA Group AG, Catalent Inc., Mettler Toledo, Patheon, Cytiva, Samsung Biologics Co.Ltd., WuXi Biologics, Syntegon Technology GmbH, Coperion GmbH, Hosokawa Micron Group, FUJIFILM Diosynth Biotechnologies, Leistritz AG, Glatt GmbH, Freund-Vector Corp., SK biotek Co. Ltd., Gericke AG, GEBRÜDER LÖDIGE MASCHINENBAU GmbH, Munson Machinery Company Inc., L.B. Bohle Maschinen und Verfahren GmbH, KORSCH AG, Chemtrix BV.
Western Europe was the largest region in the pharmaceutical continuous manufacturing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical continuous manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmaceutical continuous manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary categories of pharmaceutical continuous manufacturing products include integrated continuous systems, controls and software, and semi-continuous systems. The Integrated Continuous System (ICS) represents a comprehensive method for producing pharmaceutical items seamlessly on a continuous production line. These systems find application in the manufacturing of both large molecule and small molecule therapeutics, playing a vital role in producing solid formulations, liquids, and semi-solid formulations. ICS is deployed in various applications, including final drug product manufacturing and active pharmaceutical ingredient (API) manufacturing. This technology is adopted by diverse end-users such as pharmaceutical companies, contract manufacturing organizations, and other relevant entities in the pharmaceutical industry.
The pharmaceutical continuous manufacturing market research report is one of a series of new reports that provides pharmaceutical continuous manufacturing market statistics, including pharmaceutical continuous manufacturing industry global market size, regional shares, competitors with a pharmaceutical continuous manufacturing market share, detailed pharmaceutical continuous manufacturing market segments, market trends, and opportunities, and any further data you may need to thrive in the pharmaceutical continuous manufacturing industry. This pharmaceutical continuous manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The pharmaceutical continuous manufacturing market consists of revenues earned by entities by providing manufacturing services such as mixing, granulation, coating, and tablet compression. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharmaceutical continuous manufacturing market also includes sales of organic PCM and inorganic PCM techniques. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Pharmaceutical Continuous Manufacturing Market Characteristics3. Pharmaceutical Continuous Manufacturing Market Trends and Strategies32. Global Pharmaceutical Continuous Manufacturing Market Competitive Benchmarking33. Global Pharmaceutical Continuous Manufacturing Market Competitive Dashboard34. Key Mergers and Acquisitions in the Pharmaceutical Continuous Manufacturing Market
4. Pharmaceutical Continuous Manufacturing Market - Macro Economic Scenario
5. Global Pharmaceutical Continuous Manufacturing Market Size and Growth
6. Pharmaceutical Continuous Manufacturing Market Segmentation
7. Pharmaceutical Continuous Manufacturing Market Regional and Country Analysis
8. Asia-Pacific Pharmaceutical Continuous Manufacturing Market
9. China Pharmaceutical Continuous Manufacturing Market
10. India Pharmaceutical Continuous Manufacturing Market
11. Japan Pharmaceutical Continuous Manufacturing Market
12. Australia Pharmaceutical Continuous Manufacturing Market
13. Indonesia Pharmaceutical Continuous Manufacturing Market
14. South Korea Pharmaceutical Continuous Manufacturing Market
15. Western Europe Pharmaceutical Continuous Manufacturing Market
16. UK Pharmaceutical Continuous Manufacturing Market
17. Germany Pharmaceutical Continuous Manufacturing Market
18. France Pharmaceutical Continuous Manufacturing Market
19. Italy Pharmaceutical Continuous Manufacturing Market
20. Spain Pharmaceutical Continuous Manufacturing Market
21. Eastern Europe Pharmaceutical Continuous Manufacturing Market
22. Russia Pharmaceutical Continuous Manufacturing Market
23. North America Pharmaceutical Continuous Manufacturing Market
24. USA Pharmaceutical Continuous Manufacturing Market
25. Canada Pharmaceutical Continuous Manufacturing Market
26. South America Pharmaceutical Continuous Manufacturing Market
27. Brazil Pharmaceutical Continuous Manufacturing Market
28. Middle East Pharmaceutical Continuous Manufacturing Market
29. Africa Pharmaceutical Continuous Manufacturing Market
30. Pharmaceutical Continuous Manufacturing Market Competitive Landscape and Company Profiles
31. Pharmaceutical Continuous Manufacturing Market Other Major and Innovative Companies
35. Pharmaceutical Continuous Manufacturing Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Pharmaceutical Continuous Manufacturing Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on pharmaceutical continuous manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for pharmaceutical continuous manufacturing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Product: Integrated Continuous System; Control and Software; Semi-Continuous System
2) By Therapeutics Type: Large Molecule; Small Molecule
3) By Formulation: Solid Formation; Liquid and Semi-Solid Formation
4) By Application: Final Drug Product Manufacturing; Active Pharmaceutical Ingredient (API) Manufacturing
5) By End-Users: Pharmaceutical Companies; Contract Manufacturing Organization; Other End-Users
Key Companies Mentioned: Pfizer Inc.; Robert Bosch GmbH; Siemens AG; Novartis AG; Thermo Fisher Scientific Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer Inc.
- Robert Bosch GmbH
- Siemens AG
- Novartis AG
- Thermo Fisher Scientific Inc.
- GlaxoSmithKline Plc.
- Eli Lilly and Company
- Corning Inc.
- Vertex Pharmaceuticals
- Lonza Group Ltd.
- GEA Group AG
- Catalent Inc.
- Mettler Toledo
- Patheon
- Cytiva
- Samsung Biologics Co.Ltd.
- WuXi Biologics
- Syntegon Technology GmbH
- Coperion GmbH
- Hosokawa Micron Group
- FUJIFILM Diosynth Biotechnologies
- Leistritz AG
- Glatt GmbH
- Freund-Vector Corp.
- SK biotek Co. Ltd.
- Gericke AG
- GEBRÜDER LÖDIGE MASCHINENBAU GmbH
- Munson Machinery Company Inc.
- L.B. Bohle Maschinen und Verfahren GmbH
- KORSCH AG
- Chemtrix BV
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 175 |
Published | February 2024 |
Forecast Period | 2024 - 2028 |
Estimated Market Value ( USD | $ 2.5 Billion |
Forecasted Market Value ( USD | $ 3.71 Billion |
Compound Annual Growth Rate | 10.4% |
Regions Covered | Global |